Helsinn Group has signed a distribution and licence agreement renewal with Angelini Pharma in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic for AULIN and MESULID (Nimesulide) for the treatment of acute (short-term) pain.

Erik Lommerde, Executive VP International Operations at Angelini Pharma, remarked, “We are delighted to renew our partnership with Helsinn. This collaboration is built on a foundation of mutual trust, highlighted by our shared commitment to professional excellence, in-depth product knowledge, and high-quality service. This alliance is crucial for both parties and represents a strong business relationship.”

Dr. Melanie Rolli, Helsinn Group CEO, commented, “We are pleased to have signed this agreement with Angelini and honored to maintain our ongoing collaboration. Our long-standing partnership with Angelini exemplifies how Helsinn fosters relationships and alliances to deliver essential products to patients. We appreciate their extensive reach in these countries, which enables patient access to this much-needed treatment.”

Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology and dermato-oncology.